ArticleBulletin of the World Health Organization2025
Hepatitis B vaccination of preterm infants and risk of bronchopulmonary dysplasia: a cohort study, Australia.
Article in Bulletin of the World Health Organization, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Birth-dose hepatitis B vaccine and bronchopulmonary dysplasia risks in preterm infants.Bulletin of the World Health Organization · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine whether hepatitis B virus (HBV) vaccination of extremely preterm infants (defined in our study as < 29 weeks gestation) within 24 hours of birth (birth-dose) increases the risk of developing bronchopulmonary dysplasia. Methods: Using data from Australia, we conducted a population data linkage study using the Victorian Vaccine Safety Health Link. This platform links state-wide immunization and health outcomes from the Victorian Perinatal Data Collection and the Victorian Admitted Episodes Dataset. Our retrospective cohort study included all extremely preterm infants born alive during 2017-2020 (excluding data outliers). We investigated the relationship between birth-dose HBV vaccination and bronchopulmonary dysplasia diagnosis at 36 weeks postmenstrual age. We identified possible confounders using a directed acyclic graph, and included these confounders in a robust Poisson regression model. Findings: Of the 818 extremely preterm infants meeting our inclusion criteria, 306 received birth-dose HBV vaccination: 50.7% (155/306) of the vaccinated and 61.9% (317/512) of the unvaccinated infants developed bronchopulmonary dysplasia. After accounting for measured confounders, the adjusted relative risk was 0.83 (95% confidence interval, CI: 0.68-1.00), suggesting no increased risk. However, residual confounding by indication may still be present as it is not known how clinician perception of the stability of the newborn affects the decision to vaccinate or not, potentially underestimating any association between vaccination and outcome. Conclusion: Our findings support existing World Health Organization recommendations to immunize all infants against HBV within 24 hours of birth, including those born prematurely.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.